Announced Sun, 11 Jan · 15:44 IST

Submission of Intimation of Confirmation of director appointment in EGM.

Promoter Family Board EntryManagement Changes View source PDF

Price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve

Awaiting price reaction for this filing.

AI summary

Novelix Pharmaceuticals (formerly Trimurthi Limited) has confirmed that shareholders approved the appointment of Ms. Sridevi Belide (DIN: 10455373) as a Non-Executive Non-Independent Director at the Extra-Ordinary General Meeting held on 09 January 2026. The effective date of appointment is 23 October 2025. Ms. Belide is a medical professional (MBBS degree) and belongs to the company's promoter group, though she is not related to any existing director. The filing is a correction to an earlier submission dated 10 January 2026 that contained an incorrect brief profile.

Likely market impact

This is a routine governance update with no direct impact on financials or operations. The appointment strengthens board representation, with the new director adding healthcare expertise. Shareholders should note promoter-group representation on the board has increased.